Savara Inc (SVRA)

$5.87 -0.07 (-1.18%)
Market Cap 1.18B
Revenue (ttm) 0.00
Net Income (ttm) -118.84M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.15
Volume 992,000
Avg Vol 1,671,842
Day's Range N/A - N/A
Shares Out 204.66M
Stochastic %K 83%
Beta 0.32
Analysts Strong Sell
Price Target $10.81

Company Profile

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. was founded in 2007 and is headquartered in Langhorne, Pennsylvania.

Industry: Biotechnology
Sector: Healthcare
Phone: 512 614 1848
Address:
1717 Langhorne Newtown Road, Suite 300 One Summit Square, Langhorne, United States
Richterscale
Richterscale Apr. 10 at 4:27 PM
$SVRA Yikes we need some news…
0 · Reply
Richterscale
Richterscale Apr. 8 at 11:00 PM
$SVRA Hopefully AH holds. 🙏
0 · Reply
ckruel
ckruel Apr. 7 at 4:14 PM
$SVRA $11 Target Check out this article from TipRanks | Savara: Regulatory Momentum and Strong Efficacy Data Support Buy Rating on MOLBREEVI in Autoimmune PAP | https://tipranks.onelink.me/WJho/mtju55px
1 · Reply
DARKP00L
DARKP00L Apr. 7 at 12:18 PM
$SVRA 08:13 on Apr. 07 2026 Savara's MOLBREEVI MAA Accepted By MHRA For Autoimmune PAP, Joining Ongoing FDA And EMA Reviews With Decisions Expected Across U.S., EU, And U.K. Within 12 Months #tradeideas
0 · Reply
Richterscale
Richterscale Apr. 3 at 8:53 PM
$SVRA citizens reiterated rating to outperform and gives stock $10PT
0 · Reply
Richterscale
Richterscale Apr. 1 at 5:06 PM
$SVRA Is $6 on the horizon?
0 · Reply
Zeffanator2
Zeffanator2 Apr. 1 at 12:49 PM
$SVRA When moon?
0 · Reply
Richterscale
Richterscale Mar. 31 at 8:48 PM
$SVRA See you just had to yell at it. Lol
0 · Reply
Richterscale
Richterscale Mar. 30 at 7:18 PM
$SVRA why is this not green. F!
0 · Reply
DonCorleone77
DonCorleone77 Mar. 30 at 1:03 PM
$SVRA Savara announces EMA validation of MAA for MOLBREEVI Savara announced that the EMA has validated the submission of the MOLBREEVI MAA in autoimmune PAP; the submission will now be reviewed by the Committee for Medicinal Products for Human Use. In the U.S., the FDA is reviewing the MOLBREEVI BLA under Priority Review with an August 22, 2026 Action Date.
0 · Reply
Latest News on SVRA
Savara Announces the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) Has Accepted the MOLBREEVI* Marketing Authorisation Application (MAA) for Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

Apr 7, 2026, 8:05 AM EDT - 3 days ago

Savara Announces the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) Has Accepted the MOLBREEVI* Marketing Authorisation Application (MAA) for Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

Savara Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application (MAA) for MOLBREEVI* in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

Mar 30, 2026, 8:05 AM EDT - 11 days ago

Savara Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application (MAA) for MOLBREEVI* in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

Savara Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Update

Mar 13, 2026, 8:05 AM EDT - 4 weeks ago

Savara Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Update

Savara Provides Regulatory Update on the MOLBREEVI* Development Program in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

Mar 6, 2026, 4:05 PM EST - 4 weeks ago

Savara Provides Regulatory Update on the MOLBREEVI* Development Program in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

Savara Announces Participation in 2026 Citizens Life Sciences Conference

Mar 4, 2026, 4:05 PM EST - 5 weeks ago

Savara Announces Participation in 2026 Citizens Life Sciences Conference

Savara Announces the U.S. Food and Drug Administration (FDA) Filed the MOLBREEVI* Biologics License Application (BLA) in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

Feb 20, 2026, 4:15 PM EST - 6 weeks ago

Savara Announces the U.S. Food and Drug Administration (FDA) Filed the MOLBREEVI* Biologics License Application (BLA) in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

Savara Announces New Employment Inducement Grant

Feb 13, 2026, 4:05 PM EST - 7 weeks ago

Savara Announces New Employment Inducement Grant

Savara Announces Participation in Upcoming Investor Healthcare Conferences

Feb 4, 2026, 4:05 PM EST - 2 months ago

Savara Announces Participation in Upcoming Investor Healthcare Conferences

Savara Announces Amendment to Hercules Capital Debt Facility Providing up to $75M of Additional Debt Funding Upon U.S. Food and Drug Administration (FDA) Approval of MOLBREEVI*

Jan 27, 2026, 8:05 AM EST - 2 months ago

Savara Announces Amendment to Hercules Capital Debt Facility Providing up to $75M of Additional Debt Funding Upon U.S. Food and Drug Administration (FDA) Approval of MOLBREEVI*

HTGC

PANTHERx® Rare Selected by Savara as the U.S. Exclusive Specialty Pharmacy for MOLBREEVI*

Jan 8, 2026, 4:05 PM EST - 3 months ago

PANTHERx® Rare Selected by Savara as the U.S. Exclusive Specialty Pharmacy for MOLBREEVI*

Savara Resubmits the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

Dec 22, 2025, 8:30 AM EST - 3 months ago

Savara Resubmits the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

Savara Announces Participation in the 44th Annual J.P. Morgan Healthcare Conference

Dec 17, 2025, 8:05 AM EST - 4 months ago

Savara Announces Participation in the 44th Annual J.P. Morgan Healthcare Conference

Savara Announces European Patent Office (EPO) Intends to Grant a Patent for the Liquid Formulation of MOLBREEVI*

Dec 11, 2025, 8:05 AM EST - 4 months ago

Savara Announces European Patent Office (EPO) Intends to Grant a Patent for the Liquid Formulation of MOLBREEVI*

Savara and PARI Granted a European Patent Covering the Drug-Device Combination of MOLBREEVI* Delivered Via the Proprietary eFlow® Nebulizer System

Dec 2, 2025, 8:05 AM EST - 4 months ago

Savara and PARI Granted a European Patent Covering the Drug-Device Combination of MOLBREEVI* Delivered Via the Proprietary eFlow® Nebulizer System

Savara Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 12, 2025, 4:05 PM EST - 5 months ago

Savara Reports Third Quarter 2025 Financial Results and Provides Business Update

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of November 7, 2025 in Savara Inc. Lawsuit – SVRA

Nov 5, 2025, 5:54 PM EST - 5 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of November 7, 2025 in Savara Inc. Lawsuit – SVRA

Savara Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Total Gross Proceeds of $149.5M

Oct 31, 2025, 4:05 PM EDT - 5 months ago

Savara Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Total Gross Proceeds of $149.5M

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Savara

Oct 30, 2025, 11:05 AM EDT - 5 months ago

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Savara

Savara Announces Pricing of $130.0 Million Public Offering of Common Stock and Pre-funded Warrants

Oct 29, 2025, 9:43 PM EDT - 5 months ago

Savara Announces Pricing of $130.0 Million Public Offering of Common Stock and Pre-funded Warrants

Savara Announces Proposed Public Offering

Oct 29, 2025, 4:07 PM EDT - 5 months ago

Savara Announces Proposed Public Offering

Savara announces $75M Royalty Funding Agreement with RTW to Support the Potential Launch of MOLBREEVI* in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

Oct 29, 2025, 4:01 PM EDT - 5 months ago

Savara announces $75M Royalty Funding Agreement with RTW to Support the Potential Launch of MOLBREEVI* in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Savara

Oct 28, 2025, 9:58 AM EDT - 5 months ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Savara

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Savara

Oct 23, 2025, 1:36 PM EDT - 6 months ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Savara

Savara Announces Chief Medical Officer (CMO) Transition

Oct 17, 2025, 8:05 AM EDT - 6 months ago

Savara Announces Chief Medical Officer (CMO) Transition

SAVARA DEADLINE REMINDER: Bragar Eagel & Squire, P.C. Reminds Savara Investors to Contact the Firm Before the November 7th Deadline

Oct 14, 2025, 12:14 PM EDT - 6 months ago

SAVARA DEADLINE REMINDER: Bragar Eagel & Squire, P.C. Reminds Savara Investors to Contact the Firm Before the November 7th Deadline

SVRA INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Savara

Oct 12, 2025, 8:44 AM EDT - 6 months ago

SVRA INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Savara

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of November 7, 2025 in Savara Inc. Lawsuit - SVRA

Oct 6, 2025, 8:45 AM EDT - 6 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of November 7, 2025 in Savara Inc. Lawsuit - SVRA

Savara Announces Encore Presentations of Results From the Phase 3 IMPALA-2 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at CHEST 2025

Oct 2, 2025, 4:05 PM EDT - 6 months ago

Savara Announces Encore Presentations of Results From the Phase 3 IMPALA-2 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at CHEST 2025

Savara Presents New Data From the Phase 3 IMPALA-2 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the European Respiratory Society (ERS) Congress 2025

Sep 29, 2025, 2:00 AM EDT - 6 months ago

Savara Presents New Data From the Phase 3 IMPALA-2 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the European Respiratory Society (ERS) Congress 2025

Savara Announces New U.S. Health Claims Data Analysis Finds Over 50% Increase in the Estimated Number of Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) Patients Compared to Previous Claims Analysis

Sep 2, 2025, 9:00 AM EDT - 7 months ago

Savara Announces New U.S. Health Claims Data Analysis Finds Over 50% Increase in the Estimated Number of Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) Patients Compared to Previous Claims Analysis

New England Journal of Medicine (NEJM) to Publish Results From Savara's Pivotal Phase 3 IMPALA-2 Clinical Trial in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

Aug 20, 2025, 5:15 PM EDT - 8 months ago

New England Journal of Medicine (NEJM) to Publish Results From Savara's Pivotal Phase 3 IMPALA-2 Clinical Trial in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

Savara to Present New Data from the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the European Respiratory Society Congress 2025

Aug 18, 2025, 8:05 AM EDT - 8 months ago

Savara to Present New Data from the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the European Respiratory Society Congress 2025

Savara Reports Second Quarter 2025 Financial Results and Provides a Business Update

Aug 13, 2025, 8:05 AM EDT - 8 months ago

Savara Reports Second Quarter 2025 Financial Results and Provides a Business Update

Richterscale
Richterscale Apr. 10 at 4:27 PM
$SVRA Yikes we need some news…
0 · Reply
Richterscale
Richterscale Apr. 8 at 11:00 PM
$SVRA Hopefully AH holds. 🙏
0 · Reply
ckruel
ckruel Apr. 7 at 4:14 PM
$SVRA $11 Target Check out this article from TipRanks | Savara: Regulatory Momentum and Strong Efficacy Data Support Buy Rating on MOLBREEVI in Autoimmune PAP | https://tipranks.onelink.me/WJho/mtju55px
1 · Reply
DARKP00L
DARKP00L Apr. 7 at 12:18 PM
$SVRA 08:13 on Apr. 07 2026 Savara's MOLBREEVI MAA Accepted By MHRA For Autoimmune PAP, Joining Ongoing FDA And EMA Reviews With Decisions Expected Across U.S., EU, And U.K. Within 12 Months #tradeideas
0 · Reply
Richterscale
Richterscale Apr. 3 at 8:53 PM
$SVRA citizens reiterated rating to outperform and gives stock $10PT
0 · Reply
Richterscale
Richterscale Apr. 1 at 5:06 PM
$SVRA Is $6 on the horizon?
0 · Reply
Zeffanator2
Zeffanator2 Apr. 1 at 12:49 PM
$SVRA When moon?
0 · Reply
Richterscale
Richterscale Mar. 31 at 8:48 PM
$SVRA See you just had to yell at it. Lol
0 · Reply
Richterscale
Richterscale Mar. 30 at 7:18 PM
$SVRA why is this not green. F!
0 · Reply
DonCorleone77
DonCorleone77 Mar. 30 at 1:03 PM
$SVRA Savara announces EMA validation of MAA for MOLBREEVI Savara announced that the EMA has validated the submission of the MOLBREEVI MAA in autoimmune PAP; the submission will now be reviewed by the Committee for Medicinal Products for Human Use. In the U.S., the FDA is reviewing the MOLBREEVI BLA under Priority Review with an August 22, 2026 Action Date.
0 · Reply
DARKP00L
DARKP00L Mar. 30 at 12:18 PM
$SVRA 08:16 on Mar. 30 2026 Savara Receives European Medicines Agency Validation For Submission Of MOLBREEVI MAA In Autoimmune Pulmonary Alveolar Proteinosis #tradeideas
0 · Reply
Richterscale
Richterscale Mar. 23 at 7:38 PM
$SVRA When is next milestone?
0 · Reply
Flydown
Flydown Mar. 20 at 8:22 PM
$SVRA volume 9 milioni!
0 · Reply
art62
art62 Mar. 19 at 4:48 PM
$SVRA Adding ...good risk reward
1 · Reply
Vavavoom
Vavavoom Mar. 18 at 1:11 AM
$SVRA hmmm
0 · Reply
ghostdemon
ghostdemon Mar. 17 at 8:45 PM
$SVRA PnD scam
0 · Reply
Richterscale
Richterscale Mar. 17 at 7:58 PM
$SVRA I read they signed a long term lease agreement to move Headquarters. 5 year lease
2 · Reply
Flydown
Flydown Mar. 17 at 6:11 PM
$SVRA volume will go over 2M$ also today!
0 · Reply
Flydown
Flydown Mar. 17 at 5:58 PM
$SVRA preparing shorts squeeze!
1 · Reply
Richterscale
Richterscale Mar. 17 at 5:03 PM
$SVRA I might DCA a little more but I don’t need to get stupid either.
0 · Reply
Spacemonkey1
Spacemonkey1 Mar. 17 at 4:22 PM
$SVRA now’s a good time to buy more, this may be around the lowest it gets for a while
0 · Reply
Spacemonkey1
Spacemonkey1 Mar. 17 at 4:19 PM
$SVRA all these puts at 5….
0 · Reply